Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical validation of the tempus xT next-generation targeted oncology sequencing assay

22 Mar 2019

Abstract excerpt

// Nike Beaubier 1 , Robert Tell 1 , Denise Lau 1 , Jerod R. Parsons 1 , Stephen Bush 1 , Jason Perera 1 , Shelly Sorrells 1 , Timothy Baker 1 , Alan Chang 1 , Jackson Michuda 1 , Catherine Iguartua 1 , Shelley MacNeil 1 , Kaanan Shah 1 , Philip Ellis 1 , Kimberly Yeatts 1 , Brett Mahon 1 , Timothy Taxter 1 , Martin Bontrager 1 , Aly Khan 1 , Robert Huether 1 , Eric Lefkofsky 1 and Kevin P. White 1 1 Tempus Labs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Genomics and Rare Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31040929
DOI: 10.18632/oncotarget.26797

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical validation of the tempus xT next-generation targeted oncology sequencing assayPMID 31040929Read ↗

Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid TumorsSemantic proximity Read ↗

Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.Semantic proximity Read ↗

Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.Semantic proximity Read ↗

TruSight Oncology 500: Enabling Comprehensive Genomic Profiling and Biomarker Reporting with Targeted SequencingSemantic proximity Read ↗

Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.Semantic proximity Read ↗

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.Semantic proximity Read ↗

Analytical and Clinical Validation of a Target-Enhanced Whole Genome Sequencing-Based Comprehensive Genomic Profiling Test.Semantic proximity Read ↗

A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumoursSemantic proximity Read ↗

Validation of a next-generation sequencing assay for clinical molecular oncology.Semantic proximity Read ↗

Clinical Validation of a Novel GeneReader Next Generation Sequencing System for Tumor Specific Mutations and Bioinformatics Variant Analysis.Semantic proximity Read ↗

Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.Semantic proximity Read ↗

Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion DetectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.